Market Access

NICE relents and okays Akcea’s rare disease drug Waylivra for NHS use

https://pharmaphorum.com/news/nice-relents-and-okays-akceas-rare-disease-drug-waylivra-for-nhs-use/

BioNTech, Lilly shore up manufacturing capacity for their COVID-19 meds

https://pharmaphorum.com/news/biontech-lilly-shore-up-manufacturing-capacity-for-their-covid-19-meds/

A history of AstraZeneca

https://pharmaphorum.com/views-analysis-sales-marketing/a_history_of-_astrazeneca/

Transformational value – preparing for a decade of radical change

https://pharmaphorum.com/whitepapers/preparing-for-a-decade-of-radical-change-in-pharma-transformational-value/

Price cut wins NICE OK for AZ’s Tagrisso in untreated lung cancer

https://pharmaphorum.com/news/price-cut-wins-nice-ok-for-azs-tagrisso-in-untreated-lung-cancer/

Unpleasant truth: the pandemic, record debt and our opportunity for sustainability

https://pharmaphorum.com/views-analysis-digital/unpleasant-truth-pandemic-record-debt-sustainability/

After a nay from NICE, Scotland says aye to J&J’s Spravato

https://pharmaphorum.com/news/after-a-nay-from-nice-scotland-says-aye-to-jjs-spravato/

Rises in non-submissions to NICE: do they matter?

https://pharmaphorum.com/views-analysis-market-access/rises-in-non-submissions-to-nice-do-they-matter/

Registration opens for Pre-filled Syringes & Injectable Devices Conference 2021

https://pharmaphorum.com/partner-content/registration-opens-for-pre-filled-syringes-injectable-devices-conference-2021/

1 2 3 4 5 >»

Close in 10 seconds

Pharmaphorum.com

Search